Uni-Bio Science Group

Uni-Bio Science Group has commercialized several prescription drugs in China, including biologicals for wound healing and dry eye. Its lead pipeline assets target metabolic diseases and ophthalmology, with late-stage programs such as Uni-PTH for osteoporosis under regulatory review. The company’s GLP‑1 analogue program addresses type 2 diabetes and obesity. Manufacturing capabilities have recently expanded with a new GMP facility supporting both current products and future launches. Clinical data suggest efficacy in bone density improvement for osteoporosis therapies; regulatory filings are ongoing or pending approval for key assets like Uni-PTH and next-generation formulations of existing drugs.